Ritonavir-boosted darunavir (DRV/r) is recommended in ART-na€ıve, specifically in those with perceived low adherence and before results of resistance test. DRV/r 600/100 mg twice daily (BID) is licensed for ART-experienced, while 800/100 mg once daily formulation (QD) is recommended in first-line and in experienced patient without DRV RAMs. In clinical practice, however, a non-negligible proportion of ART-na€ıve subjects started with DRV/r BID. The aim of this study is to identify patterns of prescription of DRV/r BID in ARTnaive, analysing predictors of DRV/r BID start versus QD.
Reason for choosing darunavir/ritonavir 600/100 mg BID vs. 800/100 mg QD in ART-naive patients.
G. Nunnari;G. F. Pellicanò
2018-01-01
Abstract
Ritonavir-boosted darunavir (DRV/r) is recommended in ART-na€ıve, specifically in those with perceived low adherence and before results of resistance test. DRV/r 600/100 mg twice daily (BID) is licensed for ART-experienced, while 800/100 mg once daily formulation (QD) is recommended in first-line and in experienced patient without DRV RAMs. In clinical practice, however, a non-negligible proportion of ART-na€ıve subjects started with DRV/r BID. The aim of this study is to identify patterns of prescription of DRV/r BID in ARTnaive, analysing predictors of DRV/r BID start versus QD.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.